GSK hikes price of subsidiary Tesaro's ovarian cancer drug
As drug companies face increasing backlash over prices, pharmaceutical giant GlaxoSmithKline plc joined others in raising prices this week, including the cost of an ovarian cancer drug developed by a Massachusetts biotech.
GlaxoSmithKline (NYSE: GSK), which is based in the UK, acquired the rights to the drug Zejula when it purchased Waltham-based biotech Tesaro for $5.1 billion last year. It raised the price of the drug five percent this week, bringing the cost for a 30-day supply of 100 milligram…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Health Management | Ovarian Cancer | Ovaries | Pharmaceuticals